NCT07136493View on ClinicalTrials.gov

Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

January 12, 2026

Primary Completion Date

March 30, 2028

Study Completion Date

March 30, 2028

Conditions
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast CarcinomaHER2-Positive Breast CarcinomaTriple-Negative Breast Carcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples for ctDNA testing

PROCEDURE

Biospecimen Collection

Undergo possible collection of tissue

OTHER

Electronic Health Record Review

Ancillary studies

OTHER

Survey Administration

Ancillary studies

Trial Locations (5)

30265

NOT_YET_RECRUITING

City of Hope Atlanta Cancer Center, Newnan

60099

RECRUITING

City of Hope at Chicago, Zion

85338

RECRUITING

CTCA at Western Regional Medical Center, Goodyear

91010

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

92618

RECRUITING

City of Hope at Irvine Lennar, Irvine

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER